RFC方案治疗B细胞幼淋巴细胞白血病一例并文献复习  

Successful treatment of B cell prolymphocytic leukemia by fludarabine, cyclophosphomide and rituximab therapy： own experience and literature review

作　　者：章艳茹[1] 李增军[1] 齐军元[1] 邱录贵[1] 

机构地区：[1]300020天津,中国医学科学院北京协和医学院血液学研究所血液病医院淋巴瘤诊疗中心

出　　处：《白血病．淋巴瘤》2013年第2期91-93,97,共4页Journal of Leukemia & Lymphoma

基　　金：卫生公益性行业科研专项（201202017）;国家科技重大专项子课题（2011ZX09302-007-04）

摘　　要：目的探讨B细胞幼淋巴细胞白血病（B-PLL）临床特征。方法报道1例33岁男性B-PLL患者的临床表现和治疗经过。结果患者血小板减少、淋巴细胞增高，有全身B症状、伴随脾大和淋巴结肿大。患者拒绝异基因造血干细胞移植，予氟达拉滨、环磷酰胺联合利妥昔单抗组成的RFC方案化疗后，患者达到血液、骨髓、免疫表型完全缓解。结论RFC方案可能是B—PLL合适且有效的初始治疗选择之一。Objective To explore the clinical characteristics of B cell prolymphocytic leukemia （B-PLL）. Methods The clinical manifestation, treatment and outcome of a 33-year-old man with B-PLL were reported. Results The young patient had thrombocytopenia and systemic B-symptoms, markedly raised lymphocyte count, bulky splenomegaly and lymphadenopathy. He refused stem cell transplant, so RFC regimen （fludarabine, cyclophosphomide and rituximab） therapy were administered. After 4 cycles of RFC therapy, the patient achieved a complete immunophenotypical and hematological remission response. Conclusion RFC therapy might be a feasible and useful treatment option for B-PLL.

关 键 词：白血病 幼淋细胞 B细胞 利妥昔单抗 嘌呤核苷类似物 免疫表型完全缓解 

分 类 号：R733.71[医药卫生—肿瘤]